Agilent Partners With NUS to Advance Cardiovascular Research in Singapore
Agilent Partners With NUS to Advance Cardiovascular Research in Singapore
Agilent's integrated metabolic and cellular phenotyping platforms, such as xCELLigence, Seahorse XF, and BioTek technologies enable efficient cell studies. This will facilitate the discovery of new therapeutic targets and cardio-liver-metabolic biomarkers to prevent CVDs.The collaboration will span four years.
合作將持續四年。
Agilent Technologies has entered into a strategic partnership with the National University of Singapore (NUS), through NUS Medicine, to establish a Center of Excellence in Cell Metabolism.
安捷倫科技已通過新加坡國立大學醫學院與新加坡國立大學（NUS）建立戰略合作伙伴關係，以建立細胞代謝卓越中心。
The collaboration aims to advance research in cardiovascular and metabolic diseases over the next four years.
該合作旨在在未來四年內推進心血管和代謝疾病的研究。
Agilent's integrated metabolic and cellular phenotyping platforms, such as xCELLigence, Seahorse XF, and BioTek technologies enable efficient cell studies. This will facilitate the discovery of new therapeutic targets and cardio-liver-metabolic biomarkers to prevent CVDs.
安捷倫的綜合代謝和細胞表型分型平台，例如 xCelligence、Seahorse XF 和 BioTek 技術，可實現高效的細胞研究。這將促進發現新的治療靶標和心臟肝臟代謝生物標誌物，以預防心血管疾病。
According to GlobalData, global partnerships are expected to strengthen NUS' Project RESET, which aims to advance cardiovascular research in the country.
根據GlobalData的數據，全球合作伙伴關係有望加強新加坡國立大學的reSet項目，該項目旨在推進該國的心血管研究。
"By developing innovative, preventative healthcare strategies and enhancing local expertise in cardiovascular research, Singapore aims to reduce healthcare costs associated with CVDs. Furthermore, international collaborations will elevate Singapore's status as a hub for biomedical research, attracting investment, talent, and boosting the local economy over time," Shreya Jain, Medical Devices Analyst at GlobalData said.
「通過制定創新的預防性醫療保健策略和加強當地在心血管研究方面的專業知識，新加坡旨在降低與心血管疾病相關的醫療成本。此外，隨着時間的推移，國際合作將提升新加坡作爲生物醫學研究中心的地位，吸引投資、人才並促進當地經濟的發展。」 GlobalData醫療器械分析師Shreya Jain表示。
